Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa.
We proposed an approach based on the inhibitory sigmoid Emax model, which is often used in pharmacology, with estimation of IC50 through nonlinear regression using a standard function of the R software.
Malaria is one of the most devastating diseases in the world, affecting almost 225 million people a year, and causing over 780,000 deaths, most of which are children under the age of 5 years.
The developed ELISA can be used for quality screening of CQ in pharmaceutical formulations and for drug monitoring in malaria and in other infectious diseases, such as HIV, where CQ proved to be an effective therapeutic agent.
The malaria parasite's molecular responses to PN and CQ treatment are similar in terms of the genes and pathways affected.
Several extensive small molecule screens against growing Plasmodium falciparum have recently been published – and thousands of hit structures are now publicly available.
Activation of proteolytic cell death pathways may circumvent drug resistance in deadly protozoan parasites such as Plasmodium falciparum and Leishmania.
The Plasmodium falciparum lactate dehydrogenase enzyme (PfLDH) has been considered as a potential molecular target for antimalarials due to this parasite's dependence on glycolysis for energy production.
The proposed sampling designs in this paper are robust and efficient and should be considered in future PK studies of oral artesunate where only three or four blood samples can be collected.
The antimalarial drug chloroquine is eliminated to a significant extent by renal tubular secretion.